The DAPA-HF trial, the first to investigate the impact of SGLT-2 inhibitors on HF outcomes in patients with or without type 2 diabetes (HFrEF), demonstrated that DAPA significantly reduced the risk of worsening HF (hospitalization or an urgent visit resulting in intravenous therapy for HF) or cardiovascular death in HFrEF patients when added to standard HF treatment [8]. This evidence concerns the gene SLC5A2 and hydrops fetalis.